RAD18

Across TCGA pan-cancer cohorts, RAD18 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RAD18 data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher RAD18 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RAD18 expression acts as an unfavorable survival marker, although some lineages such as GBM and LSCC show a favorable association.

GBM, LUAD, and LSCC are the cancer types where RAD18 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.529	0.202	<.001	22	view →
LUAD	OS	Median	III,IV	0.279	0.819	.010	13	view →
LSCC	DFS	Tertile	II,III,IV	0.877	0.585	.019	4	view →
HNSC	OS	Median	III,IV	0.759	0.937	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RAD18–GBM (DFS)

Open the GBM breakdown →